Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT04993469
Recruiting Not applicable

Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery

NCT04993469 · tracked via the Priya Life Science Belgium tracker
Phase
Not applicable
Started
2021-05-27
Last updated
2023-12-22

Condition(s) studied

Gender Dysphoria

Investigational drug(s) / intervention(s)

Semmes-Weinstein monofilament testing and questionnaires

Semmes-Weinstein monofilament testing and questionnaires: Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction

Study summary

For genital gender affirming surgery, it remains unclear to what extent genital sensitivity might be expected and what the impact of this might be on sexual functioning.

Eligibility

Sex
ALL
Min age
18 Years
Max age
110 Years
Healthy volunteers
No
Inclusion Criteria: * Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations * Patient age ≥ 18 years * Transgender male, female of gender non-conforming patient with diagnosed gender dysphoria and the specific wish to undergo genital gender affirming surgery * Fit for operation, based on the surgeon's expert opinion * Patient is able and willing to attend the follow-up consultations Exclusion Criteria: * Absence of signed written informed consent and thus a patient unwilling to participate. * Patient age \< 18 years * Cisgender patients * Patients unfit for operation * Patient declares that it will be impossible for him to attend the follow-up consultations

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Ghent Ghent East-Flanders Recruiting

More University Hospital, Ghent trials in Belgium

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04993469 on ClinicalTrials.gov ↗ ← All trials in Belgium